Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p < 0.0001), PAX8 (p = 0.038; more in adenosquamous carcinoma), p40 (p < 0.0001; more in adenosquamous carcinoma), p63 (p = 0.0018; more in adenosquamous carcinoma) and MUC6 (p < 0.0001; less in adenosquamous carcinoma), HNF-1beta (p = 0.0023), vimentin (p = 0.0003), p53 (p = 0.0004), and CK7 (p = 0.0002) expression.
|
30258209 |
2019 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
TP63 (p63), a member of the tumor suppressor TP53 (p53) gene family, is essential for ectodermal tissue development and suppresses malignant progression of carcinomas.
|
30986748 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Carcinomas of the thyroid with Ewing family tumor element (CEFTEs) are small-cell thyroid tumors with epithelial differentiation that disclose p63 expression and EWSR1-FLI1 rearrangement, carry a favorable prognosis and may co-exist with papillary thyroid carcinoma (PTC) foci.
|
28236059 |
2017 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The numbers of monotonous clusters with p63 differed significantly between benign lesions, ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS) and invasive carcinomas (P < 0.001).
|
27060708 |
2016 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In contrast to conventional urothelial carcinomas that based on their expression can be equally divided into luminal and basal subtypes, micropapillary cancer is almost exclusively luminal, displaying enrichment of active peroxisome proliferator-activated receptor γ and suppression of p63 target genes.
|
26988609 |
2016 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The percentage of positive TKTL1 and p63 expression in gastric carcinomas was significantly higher than that in normal gastric mucosa tissues (P < 0.05).
|
26406948 |
2015 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CK5-positive carcinomas expressed p40 more frequently than p63 (18/19 vs. 8/19) and the staining was more marked.
|
26330357 |
2015 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MiR-944 is located in the intron of the tumor protein p63 (TP63) gene, which is frequently overexpressed in cervical carcinomas.
|
25156441 |
2015 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cytoplasmic/membranous expression of IL-23 (p19 and p40 subunits) and IL-23R, respectively were over-expressed in carcinomas versus adenomas and normal tissues (p<0.0001) but were reduced in lymph node metastases (p<0.0001).
|
25015728 |
2014 |
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.
|
23271742 |
2013 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This current classification system for high-grade subtypes, in particular the distinction between high-grade endometrioid (EEC-3) and serous carcinomas (ESC), is limited in its reproducibility and prognostic abilities.
|
22653804 |
2012 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas.
|
21765392 |
2011 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Presence of p63 in invasive breast carcinomas of luminal type, as seen at molecular level, suggests caution to include p63 as a marker of basal-like carcinomas.
|
20225093 |
2010 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We examined expressions of the p63 and p73 genes and proteins in normal biliary epithelia, biliary dysplasias, and EBD carcinomas using immunohistochemistry and RT-PCR analysis. p63 and p73 proteins were overexpressed in 26.3 and 41.0% of EBD carcinomas, respectively. p63 protein expression was more frequent in tumors with vascular invasion (P = 0.002) and distal location (P = 0.04), while p73 expression was more common in cancers with deeper tumor invasion (P = 0.04).
|
17385050 |
2007 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Importantly, when S100P and p63 were combined 95% of urothelial carcinomas were labeled by one or both markers.
|
17460449 |
2007 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
|
16445626 |
2006 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunoreactivity for p63 and p73 was evident in epithelial cells neighboring the basement membrane in developing and neoplastic odontogenic tissues. p63 expression in desmoplastic ameloblastomas was significantly higher than in acanthomatous and granular cell ameloblastomas, and ameloblastic carcinomas showed higher p63 expression than metastasizing ameloblastomas. p73 expression was significantly higher in plexiform ameloblastomas than in follicular ameloblastomas, and basal cell ameloblastomas showed higher p73 expression than granular cell ameloblastomas. mRNA transcripts for Delta Np63 and TAp73 were detected in all developing and neoplastic odontogenic tissues.
|
15752257 |
2005 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
|
15183414 |
2004 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of both p51 and p52 but not p33 and p42 were present at significantly higher levels in the carcinomas compared to the fibroadenomas (for p51, P<0.007; for p52, P<0.02; Mann-Whitney U-test).
|
15365563 |
2004 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We propose the inclusion of p63 as part of the diagnostic workup of challenging spindle cell tumors of the breast as a highly specific marker for metaplastic carcinomas.
|
15489655 |
2004 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We recently reported that impaired p63 expression is a common feature of high-grade invasive urothelial carcinomas and associates with reduced beta-catenin.
|
14654529 |
2003 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
On the basis of its consistency and magnitude of cancer cell-specific expression, we propose AMACR as an important new marker of prostate cancer and that its use in combination with p63 staining will form the basis for an improved staining method for the identification of prostate carcinomas.
|
11956072 |
2002 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Based on our findings, the balance of probabilities favors that p63 might play a role in the pattern of differentiation and in the oncogenesis of usual carcinomas of the skin.
|
12358808 |
2002 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Positive immunostaining for p63 was found in 55/68 (81%) carcinomas of 29 patients.
|
11948487 |
2002 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
It has recently been confirmed that p63 is expressed in the basal cells of normal prostate glands but not in prostatic carcinomas.
|
12185332 |
2002 |